Michael Aaron Kelly - 19 Oct 2022 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Role
Director
Signature
/s/ Carman Alenson attorney-in-fact
Issuer symbol
PRME
Transactions as of
19 Oct 2022
Transactions value $
$0
Form type
4
Filing time
21 Oct 2022, 16:30:39 UTC
Previous filing
01 Jul 2022
Next filing
10 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRME Stock Option (right to buy) Award $0 +9.01K $0.00 9.01K 19 Oct 2022 Common Stock 9.01K $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest in three equal annual installments beginning on September 13, 2022, subject to the Reporting Person's continued service on each such vesting date.